1-2 of 2
Michael Heider
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

Guus J. J. E. Heynen, Francis Baumgartner, Michael Heider, Upayan Patra, Maximilian Holz, Jan Braune, Melanie Kaiser, Isabell Schäffer, Stefanos A. Bamopoulos, Evelyn Ramberger, Arunima Murgai, Yuen Lam Dora Ng, Uta Margareta Demel, Dominik Laue, Sven Liebig, Josefine Krüger, Martin Janz, Axel Nogai, Markus Schick, Philipp Mertins, Stefan Müller, Florian Bassermann, Jan Krönke, Ulrich Keller, Matthias Wirth
Journal: Blood Advances
Blood Adv (2023) 7 (4): 469–481.
https://doi.org/10.1182/bloodadvances.2022007875
Published: 2023
Includes: Supplemental data
Journal Articles

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

Clinical Trials & Observations
Jacob Stroh, Anja Seckinger, Michael Heider, Martina Rudelius, Ruth Eichner, Markus Schick, Jolanta Slawska, Martina Emde-Rajaratnam, Hans Salwender, Uta Bertsch, Hartmut Goldschmidt, Katja Weisel, Christof Scheid, Ulrich Keller, Dirk Hose, Florian Bassermann
Journal: Blood Advances
Blood Adv (2022) 6 (2): 515–520.
https://doi.org/10.1182/bloodadvances.2021005532
Published: 2022
Includes: Supplemental data